| Date | Title | Description |
| 07.06.2025 | London’s Financial Landscape: A Dwindling Beacon for Growth | The London Stock Exchange is losing its luster. Once a vibrant hub for global finance, it now faces a troubling exodus. Companies are leaving, and the reasons are as clear as a foggy day. The latest departures highlight a growing trend that... |
| 05.06.2025 | The Exodus: UK Firms Flee to the US Market | The London Stock Exchange (LSE) is losing its luster. Once a beacon for global finance, it now faces a steady stream of departures. The latest blow comes from Invidior, a drug maker, and Wise, a fintech firm. Both companies have decided to ... |
| 05.06.2025 | UK fintech Wise ditches London primary listing for US | Money transfer firm Wise dealt a crushing blow to the London Stock Exchange on Thursday, after announcing plans to transfer its primary listing to the US.
The UK fintech’s new proposals include a dual listing in the UK and US, but with the ... |
| 05.06.2025 | Week in Business: Warning lights in the City as another firm quits London for New York | Another day, another London listed business saying sayonara to the London Stock Exchange.
On Monday, drug maker Invidior announced it will abandon its London listing and focus on the US after reviewing its structure and considering liquidit... |
| 02.06.2025 | Invidior: Drug maker ditches London for US | The London Stock Exchange suffered another blow on Monday after drug maker Invidior said it intends to abandon its London listing and focus on its primary listing in the US.
The firm said it had reviewed its listing structure and considered... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team
NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 04.12.2024 | Sinclair Announces New Executive Leadership to Support Global Growth Trajectory | Sinclair
Sinclair is excited to announce the appointment of three dynamic leaders to its executive leadership team, marking a pivotal transition in propelling Sinclair into its next phase of growth, innovation, and market leadership. Frank ... |
| 12.09.2024 | INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit | NEW YORK, Sept. 12, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the "Cla... |
| 10.09.2024 | FACTBOX European companies cut jobs as economy sputters | BusinessEmployee Health
Exploration & Production
FACTBOX European companies cut jobs as economy sputters
By ReutersSeptember 10, 202412:17 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Ite... |
| 04.09.2024 | Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights | NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the &... |
| 29.08.2024 | Navigating the Turbulent Waters of Indivior: A Tale of Collaboration and Controversy | In the ever-evolving landscape of biopharmaceuticals, partnerships can be a double-edged sword. Addex Therapeutics and Indivior PLC recently announced a significant step in their collaboration, focusing on the development of GABAB positive ... |
| 28.08.2024 | Addex collaboration with Indivior enters next stage |
Addex Therapeutics SA, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC announced the selection of clinical candidates f... |
| 28.08.2024 | Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights | NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the &... |
| 21.08.2024 | Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights | NEW YORK, Aug. 21, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between Febru... |
| 14.08.2024 | Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights | NEW YORK, Aug. 14, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between Febru... |
| 06.08.2024 | Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights | NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February ... |
| 26.06.2024 | McKinney Launches 15th Annual Food and Beverage Trends Report | Declares 2024 Consumer Macro Trend: "Vibe Whiplash"
NEW YORK, June 26, 2024 /PRNewswire/ -- Creative, media, and influencer agency McKinney has unveiled its 15th Annual Food and Beverage Trends Report, centered around the overarch... |
| 14.03.2024 | Addex to Present at the Bio-Europe Spring 2024 Conference | Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 14.11.2022 | Indivior To Acquire Opiant Pharmaceuticals | Indivior PLC, a Richmond, VA-based pharmaceutical company, acquired Opiant Pharmaceuticals (NASDAQ: OPNT), a Santa Monica, CA-based biopharmaceutical company.
Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in... |
| 27.01.2022 | Indivior : Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants | Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants January 27 2022
Download PDF
Indivior Announces Publication of Results from Buprenorphin... |
| 08.12.2021 | Indivior : to Present New Data on Buprenorphine Extended-Release at the 2021 Joint International Congress with ALBATROS and the World Association on Dual Disorder (WADD) | Indivior to Present New Data on Buprenorphine Extended-Release at the 2021 Joint International Congress with ALBATROS and the World Association on Dual Disorder (WADD) December 8 2021
Richmond, VA, December 8, 2021 - Indivior PLC (LON: INDV... |
| 16.11.2021 | Indivior : Financial Document | Indivior PLC
Jefferies London Healthcare Conference November 16, 2021
Forward-looking statements
This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertain... |
| 08.11.2021 | Indivior Presents Modelling Data on Interaction Between Buprenorphine and Fentanyl in Opioid-Naïve and Opioid-Tolerant Subjects at the 2021 American Conference of Pharmacometrics | Indivior Presents Modelling Data on Interaction Between Buprenorphine and Fentanyl in Opioid-Naïve and Opioid-Tolerant Subjects at the 2021 American Conference of Pharmacometrics November 8 2021
Data explain how buprenorphine has the potent... |
| 01.11.2021 | Indivior Presents Study at the 2021 National Correctional Health Care Conference on Factors Impacting Medications for Opioid Use Disorder Treatment Approaches in Criminal Justice-Involved Populations | Indivior Presents Study at the 2021 National Commission on Correctional Health Care Conference on Factors Impacting Medications for Opioid Use Disorder Treatment Approaches in Criminal Justice-Involved Populations November 1 2021
Richmond, ... |
| 28.10.2021 | Indivior Announces Q3 and Nine Months 2021 Results; Raises FY 2021 Guidance | Indivior Announces Q3 and Nine Months 2021 Results; Raises FY 2021 Guidance October 28 2021
Click here to view Q3 Results
Attachments
Original document
Permalink
Disclaimer
Indivior plc published this content on 28 October 2021 and is solel... |
| 14.09.2021 | Indivior : to Participate in Upcoming Healthcare Events During National Recovery Month | Indivior to Participate in Upcoming Healthcare Events During National Recovery Month
Richmond, VA, September 14, 2021 - Indivior PLC, (LON: INDV) Indivior PLC, (LON: INDV) today announced that the Company's leadership will participate in tw... |
| 29.07.2021 | Indivior : Second Quarter and First Half 2021 Financial Results Presentation | Indivior PLC
Q2 / H1 2021 Results July 29, 2021
AGENDA
Overview & Strategic Priorities Mark Crossley
Q2 / H1 Performance & FY 2021 Guidance Ryan Preblick
R&D Update Christian Heidbreder
Conclusion Mark Crossley
Q & A Mark Cr... |
| 29.07.2021 | Indivior : Announces H1 and Q2 2021 Financial Results | July 29, 2021
Indivior Announces H1 and Q2 2021 Results;
Reiterates Upgraded FY 2021 Guidance;
Initiating $100m Share Repurchase Program
Period to June 30th Q2 Q2 H1 H1
2021 2020 2021 2020
$m $m $m $m
Net Revenue 201 150 381 303
Operating P... |
| 30.06.2021 | Indivior : Raises FY 2021 Guidance | Indivior Raises FY 2021 Guidance
This release contains inside information.
Slough, UK and Richmond, VA, June 30, 2021 - Indivior PLC (LON: INDV) today announced that it is raising FY 2021 guidance to reflect increasing business momentum:
Hi... |
| 24.06.2021 | Indivior : Presents New Data at the College on Problems of Drug Dependence (CPDD) 2021 Annual Conference | Indivior Presents New Data at the College on Problems of Drug Dependence (CPDD)
2021 Annual Conference
Richmond, VA, June 24, 2021- Indivior PLC (LON: INDV) announces the presentation of new data from three posters and one late-breaking ora... |
| 24.06.2021 | Indivior Presents New Data at the College on Problems of Drug Dependence (CPDD) 2021 Annual Conference | |
| 08.06.2021 | INDIVIOR PLC
Indivior : Extends Leadership Position in Substance Use Disorder Treatment with Exclusive Agreement for Leading Asset Targeting Cannabis-Related Disorders. | INDIVIOR EXTENDS LEADERSHIP POSITION IN SUBSTANCE USE DISORDER TREATMENT WITH EXCLUSIVE AGREEMENT FOR LEADING ASSET TARGETING CANNABIS-RELATED DISORDERS
AEF0117 is a leading compound targeting the CB1 receptor; potentially represents the fi... |
| 08.06.2021 | Indivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading Asset Targeting Cannabis-Related Disorders | |
| 29.04.2021 | INDIVIOR PLC
Indivior : 2021 First Quarter Results Presentation | Indivior PLC
Q1 2021 Results April 29, 2021
Mark Crossley
Chief Executive Officer
Forward-looking statements
This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks a... |
| 29.04.2021 | INDIVIOR PLC
Indivior : Announces Q1 2021 Financial Results | April 29, 2021
Q1 2021 Results Announced; FY 2021 Guidance Reiterated.
Quarter to March 31 2021 2020
$m $m
Net Revenue 180 153
Operating Profit/(Loss) 57 (189)
Net Income/(Loss) 80 (163)
EPS/(LPS) (cents per share) 11 (22)
Adjusted Operatin... |
| 22.04.2021 | Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic | |
| 22.04.2021 | INDIVIOR PLC
Indivior : Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic | Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic
85% of participants agreed that patients with OUD experienced more barriers to care during the COVID-19 pandemic1
Study ... |
| 23.03.2021 | Indivior Recognizes Drug and Alcohol Facts Week® 2021, developed by The National Institute on Drug Abuse (NIDA) | |
| 24.09.2020 | Indivior Takes Strategic Alignment Actions | |
| 22.09.2020 | Indivior Underscores Commitment to Putting Patients First during this Recovery Month | |
| 24.07.2020 | Novartis, Gilead, GSK grab positive CHMPs; Menarini and Radius sign up to $350M partnership | → The CHMP may have given a thumbs down on SOBI’s $568 million rare disease drug, but they handed out several positive opinions, including:
Gilead and Galapagos’s JAK inhibitor filgotinib was recommended for moderate t... |
| 10.04.2019 | In combat mode, Indivior hunkers down for a war with DoJ over multibillion-dollar fraud charges | In the latest legal saga surrounding the US opioid epidemic, Indivior and the Department of Justice have exchanged their first round of shots on allegations that the UK drugmaker pocketed billions through fraudulent ... |
| 22.02.2019 | Days after Indivior launches authorized Suboxone generic, Mylan offers its copycat; In crowded CGRP market, Alder submits BLA | → After a protracted court battle in the United States to thwart generic competition of its blockbuster opioid addiction treatment Suboxone ultimately proved in vain, UK’s Indivior decided to get ahead of the curve o... |
| 30.07.2018 | As it fights looming competition on Suboxone, Indivior gets FDA OK on new schizophrenia drug | British drugmaker Indivior got the green light from US regulators to sell its schizophrenia drug Perseris — a relief, no doubt, considering the company’s ongoing exclusivity war over its staple drug Suboxone.
This ... |
| 03.01.2018 | Two biotech startups receive milestone payments | |
| 22.08.2017 | Indivior opens up a $30M R&D center; Lilly strikes discovery deal with Topas | ⇨ Eli Lilly $LLY has turned to Germany’s Topas Therapeutics for a new discovery deal covering drugs for inflammatory or autoimmune conditions. As part of the deal package Tops will get R&D support from the pharma gi... |
